Your shopping cart is empty

Subscriber login

Advanced Search

Home
Books
Conferences
DVDs
Newsletters
Form 483s
Pharma Quality Advisor
Webinar Training Pass
White Papers
Advertising/Sponsorships
About Us

Check out our free and informative ezines and sign up now

Home > Newsletters > Drug Industry Daily > Merck KGaA Pulls European Filing, Sacks Erbitux Lung Cancer Development

Drug Industry Daily

Sept. 19, 2012 | Vol. 11 No. 184

Merck KGaA Pulls European Filing, Sacks Erbitux Lung Cancer Development

Merck KGaA has withdrawn its EU marketing application for a lung cancer indication for its cancer drug Erbitux after regulatory authorities requested more clinical data.

This article is viewable by subscribers only. To view this article, please select an option below.

Subscribe
Print This Page
Email This Article
RSS
Free Trial
Archives
Sample PDF

Poland Expands List of Reimbursed Drugs, Adds New Active Substances Drugmakers: Public Education Vital to EU Online Pharmacy Verification Scheme EU-Japan Float Criteria for Developing Drugs Using Block-Copolymer-Micelles Six Months in, Drugmakers Still Overwhelmed by EU Vigilance Regs

Home
Advertising/Sponsorships
About Us
Contact Us
Site Map
Privacy Policy

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.